International Clinical Trial: Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer

Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07806110) titled 'Gemcitabine and Albumin-Bound Paclitaxel Combined With Liposomal Irenotecan (II) With or Without SHR-1701 as Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer' on Sept. 2.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: The First Hospital of Jilin University

Condition: Pancreas Ductal Adenocarcinoma

Intervention: Drug: SHR-1701

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: July 30, 2026

Target Sample Size: 62

Countr...